| Name | Title | Contact Details |
|---|
CODA Biotherapeutics` revolutionary chemogenetic platform aims to control the activity of cells to treat disease. With chemogenetics, the goal is to modify a target cell population using gene therapy to express a tunable `switch` protein. Cells modified with the `switch` can be activated or inactivated in a dose-dependent manner by a subsequently administered small molecule therapeutic, an effect that should only occur in the modified cells.
Pascal Biosciences is a biotechnology company focused on advancing innovative approaches for the treatment of cancer including cannabinoid-based therapeutics and targeted therapies. The company`s leading cannabinoid portfolio comprises a small molecule therapeutic, ST-403, that is advancing into clinical trials for the treatment of glioblastoma, and an immuno-stimulatory molecule. In addition, Pascal Biosciences is developing a B-cell targeted antibody for acute lymphoblastic leukemia and an antibody for calcium channels expressed by the immune system. Pascal is headquartered in Vancouver, Canada. The company trades on the TSX Venture Exchange under the symbol “PAS”.
CipherBio@SVB: Search life science fundraising news and data to discover innovative companies backed by venture investors https://t.co/mmTCuwa0Mc
Syreon Corporation is a Vancouver, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
ViroPharma Incorporated is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.